BioNTech, Swings

BioNTech Swings to Quarterly Profit, Lifts 2026 Revenue Midpoint and Buys a $205 Million FDA Fast Track

Published on 11/22/2026 at 02:40 | Editorial boerse-global.de
BioNTech posts €184.5M Q3 profit on €1.29B revenue, lifts full-year guidance midpoint, and buys a $205M FDA priority review voucher.
BioNTech Swings to Quarterly Profit, Lifts 2026 Revenue Midpoint and Buys a $205 Million FDA Fast Track Illustration mit AI erstellt.

BioNTech closed the third quarter of 2026 in the black, reporting a net profit of €184.5 million on revenue of €1.29 billion — a sharp turn from the loss-making stretch that has defined much of the year. The figures, released on 3 November, came alongside an upward nudge to full-year revenue guidance and fresh disclosure of a cash deal designed to speed an oncology filing through U.S. regulators.

The nine-month picture is less rosy. Across the first three quarters of 2026, BioNTech booked revenue of €1.51 billion against a net loss of €1.17 billion. Management pinned the top-line decline largely on the expected drop in demand for COVID-19 vaccines, the product line that once powered the company's pandemic-era windfall.

Guidance Midpoint Raised

For the full year 2026, the Mainz-based biotech lifted the midpoint of its revenue forecast. The company now expects sales of between €1.7 billion and €1.9 billion. Its balance sheet remains a pillar of strength: cash, cash equivalents and marketable securities stood at €16.2 billion, giving the group ample room to fund its pipeline.

Should investors sell immediately? Or is it worth buying BioNTech?

Roche and Genentech Take Over Program Costs

Alongside the quarterly update, BioNTech confirmed it had exercised an option in its collaboration with Roche and Genentech. From 1 January 2027, the partners will in principle shoulder the future research and development costs of the shared program. BioNTech retains a stake in potential licensing revenue should development and commercialization succeed.

A $205 Million Ticket for the FDA Express Lane

In a separate move announced the previous week, BioNTech agreed to buy a priority review voucher from Scholar Rock for $205 million in cash. The company intends to deploy the voucher on a future marketing application for a late-stage oncology asset. The transaction is subject to customary conditions, including clearance under the Hart-Scott-Rodino antitrust review process.

Analysts Hold Their Ground

On the sell side, the reaction was measured. J.P. Morgan's Jessica Fye raised her price target on Thursday to $93 from $92 while keeping a "Neutral" rating on the stock. Bank of America Securities, by contrast, reaffirmed its Buy recommendation on 17 November, with the call attributed to Tazeen Ahmad.

BioNTech shares slipped 0.5% to close at €73.80 on Friday, caught in a broad selloff that swept the U.S. equity market.

Ad

BioNTech Stock: New Analysis - 22 November

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

Disclaimer...
en | US09075V1026 | BIONTECH | boerse | 70543680 |